Johnson & Johnson (JNJ)vsSerina Therapeutics Inc (SER)
JNJ
Johnson & Johnson
$276.22
+1.43%
HEALTHCARE · Cap: $657.68B
SER
Serina Therapeutics Inc
$1.38
-16.36%
HEALTHCARE · Cap: $49.28M
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
JNJ
Buy54
out of 100
Grade: C-
SER
Avoid27
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Revenue surging 154.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : SER
The strongest argument for SER centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 154.9% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : SER
The primary concerns for SER are Market Cap, Profit Margin, Operating Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SER is a hypergrowth play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.21 — expect wider price swings.
SER is growing revenue faster at 154.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 27/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Serina Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Serina Therapeutics Inc is a pioneering biotechnology company focused on developing innovative solutions for unmet medical needs in oncology and neurology through its proprietary polymer-based drug delivery platform. This technology significantly enhances the efficacy of therapeutic agents, positioning Serina at the forefront of the biopharmaceutical industry. With a promising pipeline of product candidates and strategic partnerships, the company is well-equipped to drive sustainable growth and deliver impactful healthcare solutions, all while creating substantial value for its investors.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?